Nektar's Alopecia Treatment Shows Strong Phase 2 Results, Paving Way for Registrational Trials
NKTR has more than doubled off its 52-week low of $7.99.
Summary
Nektar Therapeutics announced positive midstage (Phase 2) clinical trial results for rezpegaldesleukin, its treatment for severe alopecia areata. The study demonstrated that over a third of patients achieved at least a 50% improvement in severity scores after 52 weeks, and nearly half saw a 30% improvement, both compared to placebo. These promising results de-risk the asset and support the company's plan to advance rezpegaldesleukin into registrational (Phase 3) trials. For a clinical-stage biotech, positive data from a key pipeline candidate is a significant value driver and could lead to increased investor confidence. Investors will now monitor the initiation and progress of the planned Phase 3 trials and the presentation of these results at an upcoming medical conference.
At the time of this announcement, NKTR was trading at $85.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.99 to $86.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.